Most recently, the Company provided an update on its study to...

Most recently, the Company provided an update on its study to evaluate the ability to genetically engineer Cymerus MSCs for the treatment of cancer. The first stage of the study, taking place in partnership with Harvard Medical School, has found that Cymerus MSCs can be successfully engineered to become cells that can express diagnostic and therapeutic proteins, which detect and prevent diseases (including cancers) using unique genetics that have been engineered by the study’s lead investigator. The ability to genetically engineer the Cymerus MSCs also opens up additional potential applications for the Cymerus platform.